SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-025077
Filing Date
2020-05-13
Accepted
2020-05-13 16:21:08
Documents
62
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ngm-10q_20200331.htm 10-Q 2015139
2 EX-31.1 ngm-ex311_6.htm EX-31.1 15881
3 EX-32.1 ngm-ex321_7.htm EX-32.1 7287
  Complete submission text file 0001564590-20-025077.txt   7184746

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT ngm-20200331.xml EX-101.INS 1583253
5 XBRL TAXONOMY EXTENSION SCHEMA ngm-20200331.xsd EX-101.SCH 53517
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ngm-20200331_cal.xml EX-101.CAL 40157
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ngm-20200331_def.xml EX-101.DEF 178638
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE ngm-20200331_lab.xml EX-101.LAB 412012
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ngm-20200331_pre.xml EX-101.PRE 317392
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38853 | Film No.: 20873448
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences